Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (noting a discrepancy with the request metadata which listed "Cypherpunk Technologies Inc.") on June 16, 2022. The filing details the results of the Company's 2022 Annual Meeting of Stockholders held on the same date. Leap Therapeutics is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Market under the symbol LPTX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report regarding voting results and does not contain financial performance data.
Material Changes and Voting Results
The report outlines the final voting results for three matters submitted to stockholders:
- Election of Directors: Two Class II director nominees were elected to serve until the 2025 annual meeting:
- William Li, MD: 41,296,078 votes For; 3,520,526 votes Withheld.
- Thomas Dietz, PhD: 41,253,895 votes For; 3,562,709 votes Withheld.
- Equity Incentive Plan: The Leap Therapeutics, Inc. 2022 Equity Incentive Plan was approved with 38,627,330 votes For and 5,918,232 votes Against.
- Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified with 64,516,555 votes For and 201,977 votes Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is strictly limited to the disclosure of shareholder voting outcomes.
Investor Verification Checklist
- Verify the correct registrant name is Leap Therapeutics, Inc. (LPTX), as the request metadata contained an incorrect company name.
- Confirm the tenure of the newly elected directors (William Li and Thomas Dietz) extends through the 2025 annual meeting.
- Review the approved 2022 Equity Incentive Plan details in subsequent filings to understand potential dilution impacts.
- Note that EisnerAmper LLP has been ratified as the auditor for the fiscal year ending December 31, 2022.